WebDec 13, 2024 · The first trial was conducted predominantly in Europe, and it worked on the basis that bortezomib, melphalan, and prednisone was an accepted regimen in European circles for treatment of myeloma in older individuals, and to which the trial then looked at VMP [ bortezomib, melphalan, prednisone] versus VMP [bortezomib, melphalan, … WebIn this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib,...
Daratumumab plus Bortezomib, Melphalan, and …
WebDec 9, 2024 · The early experience with quadruplet regimens in NDMM was evaluated in 2 randomized phase 3 trials: ALCYONE and CASSIOPEIA. 10, 11 The ALCYONE study evaluated bortezomib-melphalan-prednisone with or without daratumumab in transplant-ineligible patients with NDMM. WebJul 21, 2014 · Official Title: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in … total area of a triangle
Bortezomib, Melphalan, and Prednisone With or Without …
WebAug 25, 2024 · Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. WebJun 2, 2024 · In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes … WebApr 8, 2024 · In the updated analysis of ALCYONE trial , adding daratumumab to VMP continues to prolong PFS (median 37.3 months vs. 19.7 months for D-VMP and VMP, ... The Myeloma XI trial and a second meta-analysis confirmed these data, reporting HR of 0.47 and 0.72 for PFS and OS, respectively. total area of andhra pradesh